Generare secures €20M to expand microbial genome decoding
Paris-based biotech startup Generare has raised €20 million to accelerate its mission of generating novel, high-quality molecular data for drug development by decoding microbial genomes. The fresh capital will support technology scaling, data platform expansion and new partnerships with pharmaceutical and biotech companies.
A data-first approach to next-generation therapeutics
Generare focuses on unlocking the untapped potential of the microbial world. By systematically decoding and functionally characterizing microbial DNA, the company builds large, proprietary datasets that can be used to discover new drug targets, optimize biologics, and identify promising small-molecule candidates.
The startup combines high-throughput genomics, advanced molecular biology workflows and proprietary AI algorithms to transform raw genomic sequences into actionable biological insights. This data-centric model aims to reduce the cost, time and risk traditionally associated with early-stage drug discovery.
Strengthening collaborations with pharma and biotech
With this funding, Generare plans to deepen collaborations with global pharmaceutical and biotech partners seeking differentiated molecular assets. The company’s platform is designed to plug into existing discovery pipelines, providing validated molecular data that can accelerate hit identification and lead optimization.
The new capital will also be used to expand the company’s scientific team in Paris, invest in automated laboratory infrastructure, and scale its secure data infrastructure for enterprise clients. By industrializing the generation of high-quality molecular datasets, Generare aims to position itself as a critical infrastructure player for data-driven life sciences.
Microbial genomes as a frontier for innovation
The global race to harness microbiome and microbial genetics is intensifying, as researchers increasingly recognize microbes as a rich source of novel enzymes, metabolites and therapeutic mechanisms. Generare is betting that systematically decoding this vast biological space will unlock new classes of therapies, from next-generation antibiotics to precision immunotherapies.
As pharmaceutical pipelines face rising R&D costs and mounting pressure to innovate, platforms that can deliver robust, reproducible molecular data are gaining strategic importance. With its latest funding, Generare is poised to become a key European player at the intersection of biotechnology, genomics and AI-driven drug discovery.